- Home
- EVGN vs CMMB Comparison
EVGN vs CMMB Comparison
Compare EVGN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVGN
- CMMB
- Stock Information
- Founded
- EVGN 1999
- CMMB 2004
- Country
- EVGN Israel
- CMMB Israel
- Employees
- EVGN N/A
- CMMB N/A
- Industry
- EVGN Agricultural Chemicals
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- EVGN Industrials
- CMMB Health Care
- Exchange
- EVGN Nasdaq
- CMMB Nasdaq
- Market Cap
- EVGN 15.8M
- CMMB 15.8M
- IPO Year
- EVGN N/A
- CMMB N/A
- Fundamental
- Price
- EVGN $2.82
- CMMB $1.51
- Analyst Decision
- EVGN Strong Buy
- CMMB Strong Buy
- Analyst Count
- EVGN 1
- CMMB 3
- Target Price
- EVGN $12.00
- CMMB $5.67
- AVG Volume (30 Days)
- EVGN 23.7K
- CMMB 206.1K
- Earning Date
- EVGN 11-13-2024
- CMMB 11-07-2024
- Dividend Yield
- EVGN N/A
- CMMB N/A
- EPS Growth
- EVGN N/A
- CMMB N/A
- EPS
- EVGN N/A
- CMMB N/A
- Revenue
- EVGN $9,449,000.00
- CMMB N/A
- Revenue This Year
- EVGN $173.12
- CMMB N/A
- Revenue Next Year
- EVGN $33.10
- CMMB N/A
- P/E Ratio
- EVGN N/A
- CMMB N/A
- Revenue Growth
- EVGN 290.29
- CMMB N/A
- 52 Week Low
- EVGN $2.29
- CMMB $0.42
- 52 Week High
- EVGN $10.40
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- EVGN 42.32
- CMMB 43.28
- Support Level
- EVGN $2.63
- CMMB $1.29
- Resistance Level
- EVGN $3.32
- CMMB $1.58
- Average True Range (ATR)
- EVGN 0.26
- CMMB 0.15
- MACD
- EVGN 0.09
- CMMB -0.04
- Stochastic Oscillator
- EVGN 51.46
- CMMB 39.29
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.